In a recent interview, Ian Lance, joint-manager of the Temple Bar Income trust which focuses on value investing, explained that he feels London-listed stocks are now even more undervalued compared to international peers than over recent years:
“We think Britain’s stock market looks very cheap compared with the rest of the world. It is at a discount of around 45pc to the global market, compared with a long-run average of around 17pc. This is partly because of weakness in the pound as investors grow more fearful of a recession.”
It has been argued for a decade that companies have seen their valuations penalised for the simple fact of being listed in London. International investors started taking a cautious approach to exposure to the UK as a result of the sluggish recovery from the international financial crisis over a decade ago. That trend intensified over the Brexit period with investors taking their traditional approach to uncertainty by avoiding it.
The recent weakening of the pound against especially the dollar but also most other major international currencies is now reinforcing the discount that London-listed companies trade at compared to international peers. Even London-listed companies that make the lion’s share of their revenues and profits internationally have not escaped the London discount.
A further factor acting as a drag on the LSE is that it is dominated by cyclical companies like retailers of consumer discretionary products, financial services companies, hospitality and construction.
With it broadly accepted we are on the cusp of a recession across much of the developed world, investors are dumping exposure to cyclical stocks, further suppressing valuations. The result is that cyclical stocks are looking cheap again as markets follow their well-worn pattern of over-reacting to both positive and negative news.
Distinguishing between cheap stocks and value traps
When looking for value investments, the biggest pitfall investors face is the danger of mistaking a value trap for cheapness. Sometimes companies can look cheap compared to both their fundamentals and historic multiples but face risks and are contending with problems not yet highlighted by management or analysts.
If these issues, which market participants have recognised despite their lack of public coverage, are not taken account of in guidance, forecasts or most third-party analysis, less experienced investors can see value. The reality is the current price is a value trap and has been discounted by the market for good reason.
There are a number of common ways to distinguish a value trap from value when assessing a stock for true ‘cheapness’ when its p/e ratio jumps out as attractive. You should always ask the following questions:
Is the company underperforming its sector?
It always make sense to judge an individual stock in the context of its broader sector. If it has seen lower growth than peers look for the reasons why that is the case. Are they transient in nature or deep lying issues?
Is the company’s market share declining?
Companies can remain profitable for some time despite declining market share, especially if they are a high margin business. But if market share is locked into a long term downward trajectory there is probably a good reason why it is no longer competitive with rivals. You want to avoid buying in at the point the stock’s fundamentals still look superficially solid but are heading in a direction that will eventually mean that is no longer the case.
Is capital allocation efficient?
Assessing the efficiency of capital allocation can be tricky as it involves a level of understanding of the sector. However, if a company has been investing significant amounts of its free cash flow in a way that has not been delivering growth, it’s a warning sign that things may not be heading in a promising direction.
Sometimes it’s difficult to tell if capital is being allocated efficiently or not. An example would be Facebook owner Meta Platform’s heavy investment in the metaverse or a traditional car maker investing heavily in EV technology.
These investments could pay off spectacularly if they come off. If they don’t, they could potentially undermine the long term viability of the company if too much is riding on them.
In other cases, it’s far easier to judge. For example, if a company has recently allocated significant capital to acquiring assets that are not performing or have already seen their value written down significantly.
Does management have a history of over-promising and under-delivering?
One strong indicator of a potential value trap is a company with a record of missing publically announced targets and forecasts. This indicates a disconnect between management and operations which rarely ends well.
How much debt is the company carrying?
A common mistake less experienced investors make is failing to take a company’s level of debt into account when assessing its current performance and potential. Always look at the Debt to Equity ratio and compare it to peers.
Is the company overly reliant on a particular product or market cycle?
Sometimes companies make a lot of money from a single product or temporary surge in demand. A good example of this would be stocks that saw their revenues surge during the Covid-19 pandemic. Several vaccines and biotech companies saw their valuations shoot up as a result of the roll-out of coronavirus vaccines they produced or licensed their technology to.
However, those whose revenues were most heavily influenced by the vaccine roll-out quickly saw their valuations deflate again when the initial rush of demand started to ebb. The same can be said of other companies such as the upmarket exercise bike company Peleton, which saw its valuation go into orbit on the back of sales during lockdown periods before plunging again when they started to return towards historical norms.
Has the stock’s value dropped sharply over a short period?
On the one hand, buying into a stock that has dropped in value sharply and then goes on to have a V-shaped recovery is every investor’s dream. Unfortunately, the reality is that stocks that plunge by 30% or more over a short period almost always take a long time to recover, if they ever do.
Yes, you are looking for value which often means a stock is a long way off its peaks. But be very wary of companies that suddenly look cheap very quickly. There’s probably a good reason.
Has the stock traded at low multiples for a long time?
While you should be careful of stocks that quickly drop to trading at low multiples over a short period the same can be said of those that have done so for an extended period. That’s usually because the market sees little growth potential and a company treading water. Even if treading water takes up little energy, staying in one place for too long almost always ultimately ends in eventually sinking.
5 UK stocks that do look like they represent value, not a value trap
A recent Forbes article highlights 5 London-listed stocks that, according to a filter tool that looks for companies with strong 10-year revenue per share growth rates (at least 6%), and takes into account analysts’ future earnings projections and attractive p/e ratios, look undervalued. They are:
A construction and industrial equipment rental business, Ashtead Group may struggle during a recession and markets have priced that in with its share price falling by over 29% so far this year. At its current market cap of £18.82 billion, Ashtead now has a p/e ration of around 18 as well as a price-book ratio of 4.21 and price-sales ratio of 2.9.
Other positives are a positive return on capital invested and strong profitability despite a declining operating margin influenced by inflations. Return on equity, assets and capital are also all better than the majority of its peers.
The filters used also pinpoint asset manager Schroders as looking undervalued at its current market cap of £7.24 billion. It has a p/e ratio of just 13.08, a price-book ratio of 1.77 and price-sales ratio of 2.5.
The company is almost 220 years old and shows good profitability and steady revenue and earnings growth. Operating margins are sliding but but returns are still in the top 50% for the sector.
Paper and packaging company Mondi is not an exciting stock but has a strong history of reliable returns and currently trades at a p/e of just 6.43, a price-book ratio of 1.42 and a price-sales ratio of 0.91.
The company is still creating value for investors and has good profitability and returns that outperform competitors despite contracting operating margins.
With its strong growth, good market share, customer loyalty and relationships with premium brands, JD Sports was relatively recently a darling of investors. However, it’s had a tough year with its value down over 40% in a trend that has caught up a majority of retailers of consumer discretionary goods.
After its fall in value from recent highs, JD Sports trades at a p/e ratio of 17.78, a price-book ratio of 3.39 and a price-sales ratio of 0.75.
JD Sports is still highly profitable and its operating margin is actually improving while returns are among the best for its sector. This stock looks particularly undervalued at its current price.
Another stock that looks significantly undervalued is the Irish provider of sales, marketing and support services DCC. Its current p/e is 15.13, price-book ratio 1.62 and price-sales ratio 0.27.
Value is being created by its capital investments and profitability in a good place with returns outperforming over half of its sector competitors. The company also has a history of consistent earnings and revenue growth.The post These UK stocks look even more undervalued after pound sterling’s fall first appeared on Trading and Investment News. recession pandemic coronavirus covid-19 stocks currencies pound vaccine lockdown recession recovery uk
Rent Control Is A Disaster – Don’t Let It Spread Across The Nation
Rent Control Is A Disaster – Don’t Let It Spread Across The Nation
Authored by Betsy McCaughey via The Epoch Times,
America’s renters -…
America’s renters - more than one-third of the nation’s households - are in for trouble.
Left-wing politicians are demanding rent regulation from coast to coast. Wherever it is adopted, the result will be a disastrous reduction in the rental housing supply, leaving renters desperate for places to live.
New York is the poster child for the failures of rent regulation. The U.S. Supreme Court is currently mulling a challenge to the constitutionality of the city’s rent regime.
Whatever the justices decide, the public needs to consider less destructive, more targeted ways to help low-income people pay for housing. The court of public opinion needs to consider these facts.
Fact No. 1: Rent regulation isn’t targeted to the poor.
In New York, there’s no means test. What you need is luck or connections. The mean income of a rent-stabilized apartment dweller is $47,000, but census data show that tens of thousands of them earn more than $150,000 per year. Some occupants use what they’re saving on rent to pay for a weekend place in the Hamptons or New England.
The pols don’t object—a sure sign they’re calling for rent regulation to help themselves politically, not the poor.
In New York, 44 percent of rental apartments are regulated by the Rent Guidelines Board (RGB), established in 1969, which sets the maximum amount by which landlords are allowed to raise the rent. Those limits apply to all buildings of six or more units built before 1974.
In 2022, the RGB set the maximum rent hike at 3.25 percent on one-year leases and this year at 3 percent. Never mind that last year, fuel costs to heat the buildings soared by 19 percent and overall inflation hit 8.3 percent.
The decisions are political, not economic. Many Democratic politicians vilify building owners as “greedy landlords” and depict themselves as the champions of the downtrodden. It’s a scam.
Fact No. 2: Winners and losers.
The winners are the lucky few with rent-regulated apartments and the pols who count on an army of tenant activists to turn out at the polls. The losers are the 56 percent of renters who don’t score a regulated apartment and have to scour neighborhoods for an unregulated place that they can afford. They’re paying more.
Why? Because regulation causes some landlords to walk away, reducing the overall supply of apartments. The laws of supply and demand mean rents go up. New Yorkers in unregulated apartments are paying the highest rents in the United States for a one-bedroom apartment. They're the real victims, and they should be furious.
Yet the left-wing press pretends that rent control offers only benefits. The New Republic warns that the Supreme Court challenge threatens “laws that have benefitted the city’s tenants for generations.” Sorry, untrue—only some tenants, and not always the neediest.
It’s economic madness. The saner way to help those who need assistance paying rent is with a voucher. We offer the needy SNAP debit cards to help them pay for groceries. No one slaps price controls on grocery stores or designates certain stores as “regulated,” forcing them to sell at below cost.
Yet New York forces certain landlords to pay what should be a public cost shared by all, an argument made to the court.
Fact No. 3: The Marxist fantasy that rent regulation will help the poor is spreading across the United States and Europe as well.
Maine and Minnesota have enacted laws allowing municipalities to impose rent regulations. In November 2024, California voters will be asked to approve a proposition allowing local governments to add additional restrictions to the state’s existing rent caps.
The laws of supply and demand are international. Berlin froze rents in 2019, and the rental supply plummeted, according to the Ifo Institute, a think tank.
Yet London Mayor Sadiq Khan is calling for freezing rents for two years. London provides housing vouchers to the poor—a smarter approach—but when the city froze the voucher amounts during the COVID-19 pandemic, fewer apartments were available in the price range. The answer is to raise the voucher amount. Freezing rents will only make the shortage worse.
Ignore the demagogues. The evidence is in: Rent regulation is a political scam. There are better ways to help Americans afford a place to live.
China’s Birth Rate Plummets 10% To Lowest On Record
China’s Birth Rate Plummets 10% To Lowest On Record
China’s birthrate fell 10% last year to its lowest level on record, a significant drop…
China's birthrate fell 10% last year to its lowest level on record, a significant drop in spite of extensive efforts by the CCP to encourage people to get busy.
The country had just 9.56 million births in 2022, the lowest figure since they began keeping records in 1949, according to a report by the National Health Commission.
The high costs of child care and education, growing unemployment and job insecurity as well as gender discrimination have all helped to deter many young couples from having more than one child or even having children at all. -NBC News
China's population also fell for the first time in six decades, dropping to 1.41 billion people - a demographic shift that's caused officials to worry that the country will 'get old before it gets rich' - with a slowing economy and declining tax receipts amid increases in government debt due to soaring health and welfare costs.
According to the report, the demographic downturn is largely thanks to China's one-child policy imposed between 1980 and 2015. Nearly 40% of Chinese babies last year were the second child of a married couple, while 15% were from families with three or more children.
The sharp decline in births comes despite Beijing's efforts to increase child care and provide other financial incentives. In May, President Xi Jinping presided over a panel to study the topic.
Not just China
As we noted in June, Japan's birth rate has also plummeted to a record low for the seventh straight year, with the number of babies born falling below 800,000 this year, health ministry data showed on June 2.
The number of newborns in Japan fell to 770,747 this year, down 40,875 from the previous year and the lowest since the country began record-keeping in 1899, Kyodo News reported, citing health ministry data.
Japan’s fertility rate—the average number of children born to a woman in her lifetime—fell from 1.30 in 2021 to 1.26 last year, equivalent to the previous low recorded in 2005. The number is far below the 2.07 rate necessary to sustain a stable population.
The decline in Japan’s birth rate is attributed to people delaying parenthood due to the economic impact brought on by the COVID-19 pandemic, as well as the prevailing trend among couples to delay marriage, according to the report.
The US birthrate has also been in decline, falling slightly in 2022 compared to 2021, with roughly 3.7 million babies born nationwide. It still hasn't recovered to pre-pandemic levels according to the CDC.
And as Mike Shedlock noted two years ago.
More via Mish Talk, worth a review:
The Pandemic Caused a Baby Bust, Not a Boom
Scientific American reports The Pandemic Caused a Baby Bust, Not a Boom
When the COVID pandemic led to widespread economic shutdowns and stay-at-home orders in the spring of 2020, many media outlets and pundits speculated this might lead to a baby boom. But it appears the opposite has happened: birth rates declined in many high-income countries amid the crisis, a new study shows.
Arnstein Aassve, a professor of social and political sciences at Bocconi University in Italy, and his colleagues looked at birth rates in 22 high-income countries, including the U.S., from 2016 through the beginning of 2021. They found that seven of these countries had statistically significant declines in birth rates in the final months of 2020 and first months of 2021, compared with the same period in previous years. Hungary, Italy, Spain and Portugal had some of the largest drops: reductions of 8.5, 9.1, 8.4 and 6.6 percent, respectively. The U.S. saw a decline of 3.8 percent, but this was not statistically significant—perhaps because the pandemic’s effects were more spread out in the country and because the study only had U.S. data through December 2020, Aassve says. The findings were published on Monday in the Proceedings of the National Academy of Sciences USA.
Birth rates fluctuate seasonally within a year, and many of the countries in the study had experienced falling rates for years before the pandemic. But the declines that began nine months after the World Health Organization declared a public health emergency on January 30, 2020, were even more stark. “We are very confident that the effect for those countries is real,” Aassve says. “Even though they might have had a bit of a mild downward trend [before], we’re pretty sure about the fact that there was an impact of the pandemic.”
Covid Accelerated the Existing Trend
Covid accelerated the already declining birth rates.
Given the 16-year lag between births and the civilian noninstitutional population coupled with the aging of the workforce there will be fewer and fewer workers supporting retired workers on Social Security.
Notice the relatively steep decline in the birth rate starting in 2008 and continuing through today.
That impact will start showing up in 2024 and last a minimum of 12 years.
How long depends on whether the birth rate picks up after Covid. I highly doubt the birth rate will pick up.
Deflationary and Inflationary Impacts
- Inflationary: Shortage of workers increases wage pressures
- Deflationary: Fewer workers support an increasing number of retirees
- Deflationary: Older workers need more assistance, buy fewer things, travel less.
- Deflationary: More government debt and deficits. Government spending has a negative impact on real GDP.
* * *
Time for another sexual revolution?
TDR’s Top 7 Cannabis Developments For The Week Of October 9
Welcome to TDR’s review of the Top 7 Cannabis Developments for the week of October 9. Aside from presenting a synopsis of news events, interviews and…
Welcome to TDR’s review of the Top 7 Cannabis Developments for the week of October 9. Aside from presenting a synopsis of news events, interviews and closing market prices for publicly-listed companies.
Trulieve Cannabis announced the filing of amended federal tax returns with refund claims for several of the company’s business entities for the years 2019, 2020, and 2021. In total, the company is claiming a refund of $143 million from taxes paid which the company believes it does not owe, although there is no guarantee of receipt.
Trulieve believes its determination is supported by legal interpretations that challenge the company’s tax liability under Section 280E of the Internal Revenue Code.
The Cannabist Company Holdings has delivered a notice of partial redemption to the holders of the company’s outstanding 13% senior secured notes due May 14, 2024. The Notice provides that the company will, on October 23, 2023, redeem US$25 million of the total US$38.2 million principal amount of the Notes currently outstanding.
On the Redemption Date, Holders of Notes will have a portion of their 13% Notes, in denominations of $1,000, redeemed effective as of the Redemption Date on a pro rata basis in accordance with the terms of the trust indenture between the company and Odyssey Trust Company dated May 14, 2020, as amended and supplemented.
Cannabis consumers who caught COVID-19 had significantly lower rates of intubation, respiratory failure and death than people who do not use marijuana, according a new study based on hospital data that was presented this week at the annual conference of The American College of Chest Physicians (CHEST) in Honolulu.
Authors analyzed records from 322,214 patients from the National Inpatient Sample, a government database that tracks hospital utilization and outcomes. Of those patients, 2,603—less than 1 percent—said they consumed cannabis.
Chart Of The Week—Select MSOs Net Cash Flows After Interest Expense, CAPEX, Taxes And Debt Maturities
Interview Of The Week: Jason Wild Speaks On The Eve Of TerrAscend’s Investor Day
Georgia To Become First State Selling Medical Marijuana In Pharmacies
Widely Held MSOs & LP Weekly Performance
|Company||Symbol||Previous Week Close||End Of Week Close||% Change On Week|
|AdvisorShares Pure Cannabis ETF||MSOS||7.08||7.04||-0.56|
|Green Thumb Industries||GTBIF||10.12||9.75||-3.65|
|High Tide Inc.||HITI||1.65||1.54||-6.66|
The U.S. Census Bureau has released its first report on state-level marijuana tax revenue data following what the agency calls “a complete canvass of all state agencies” going back to July 2021. In the 18-month period between then and the end of 2022, the data show, states collected more than $5.7 billion from licensed cannabis sales.
The launch of the report, which the agency plans to update on a quarterly basis going forward, signals that at least some parts of the federal government are now beginning to treat the cannabis industry as a legitimate sector of the economy. The Census Bureau first announced in January 2021 that it would begin collecting marijuana tax figures for its quarterly summary of state and local government tax revenue. It also said it wants states to submit cannabis revenue data as part of annual reports as well.
In the news…
4Front Ventures has agreed to issue 1,283,425 subordinate voting share purchase warrants pursuant to an amendment to a previously entered promissory note purchase agreement. Pursuant to the Agreement, the lender has agreed to extend the maturity date of its loan, which has a principal amount of US$2,000,000, with a payment of an extension fee of C$65,000, which is payable in Warrants.
Aleafia Health announced that Red White & Bloom Brands Inc. has been selected as the successful bidder pursuant to the court-approved sale and investment solicitation process in connection with the previously announced proceedings of Aleafia and certain of its subsidiaries under the companies’ Creditors Arrangement Act.
BioHarvest Sciences announced that VINIA, its flagship nutraceutical product derived from red grape cells, has received its Canadian product license from Health Canada’s Natural and Non-Prescription Health Products Directorate.
California Governor vetoes cannabis cafe and marijuana labeling bills…
Canopy Growth has received EU GMP certification from RP Tuebingen, Regional Health Inspectorate of Baden-Wuerttemberg for the company’s cannabis cultivation facility in Kincardine, Ontario.
Cardiol Therapeutics announced positive study results from one of its international collaborating research centers demonstrating that subcutaneously administered cannabidiol, the active pharmaceutical ingredient in Cardiol’s novel CRD-38 subcutaneous formulation prevented increases in key cardiac inflammatory and remodelling markers in a model of heart failure.
Charlotte’s Web Holdings announced the appointment of Angela McElwee to its Board of Directors.
CLS Holdings USA announced its financial results for the fiscal quarter ended August 31, 2023.
Colorado cannabis sales surpassed the $15 billion mark in August – a milestone since legal adult-use sales launched in the state in 2014.
Connecticut cannabis sales hit $25.2M in September 2023…
Cresco Labs announced the launch of its Good News brand in the Commonwealth of Pennsylvania.
Curaleaf Holdings will report its financial and operating results for the third quarter ended September 30, 2023 after market close on November 9, 2023.
Curaleaf Holdings has filed its application to list the Company’s subordinate voting shares on the Toronto Stock Exchange.
Eurofins CDMO Alphora Inc. announced that it has received its Health Canada Cannabis Drug License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario operations in September 2023.
Goodness Growth Holdings and Grown Rogue International, Inc. have completed the issuance of warrants to purchase listed shares as previously announced on May 25, 2023.
Heritage Cannabis Holdings announced the procurement of an EU GMP certified extraction machine to be added to the existing fleet of extractors which will double the company’s hydrocarbon processing capacity.
iAnthus Capital Holdings announces that Robert Galvin will transition out of his role as Interim Chief Operating Officer of the Company, effective immediately.
IM Cannabis, a medical cannabis company with operations in Israel and Germany, releases message from the CEO about the Israel-Hamas War and announces the company, through its wholly-owned subsidiaries, IMC Holdings Ltd. and Rosen High Way Ltd., has secured C$1,390,000 in short-term debt.
IM Cannabis announced that Uri Birenberg will join the company’s leadership team as Chief Financial Officer effective October 10, 2023.
Lead GOP Senate cosponsor of a bipartisan marijuana banking bill says a planned floor vote is on pause until he can ensure the legislation will later pass the Republican-controlled House, according to a cannabis financing executive who spoke with the senator this week.
Legislative Review of the Cannabis Act: What We Heard Report
Letter to Attorney General Garland and DEA Administrator Milgram urging halt to rescheduling process.
MariMed, Inc announced “Small Batch Exclusives,” a unique, limited-time program that gives customers the opportunity to purchase legendary flower strains.
MariMed Inc. retail footprint has once again expanded, as the company officially unveiled an adult-use Thrive dispensary in Casey, Illinois. This marks the fifth dispensary in operation within the state of Illinois and the 12th dispensary in MariMed’s expanding portfolio across five states.
Organigram Holdings has obtained a receipt for a final short form base shelf prospectus filed with the securities commissions in each of the provinces and territories of Canada. A corresponding shelf registration statement on Form F-10 has been filed with the United States Securities and Exchange Commission (SEC File No. 333-274686) but is not yet effective.
RISE Dispensaries owned by Green Thumb Industries Inc. announced that RISE Dispensary Brandon, the Company’s 9th retail location in Florida, will open on October 14th.
SAFE Banking now with 84 co-sponsors…
SunStream Bancorp announced a receivership court order granting the sale of certain assets of Greenpeak Industries Inc. and certain affiliated entities d.b.a. Skymint to Skymint Acquisition Co., a newly formed designee entity of Tropics LP. Tropics is a limited partnership fully owned by an affiliate of Sunstream, a joint venture sponsored by SNDL Inc.
Texas activists say they have secured enough signatures to put a local marijuana decriminalization initiative on the ballot in the city of Lubbock if lawmakers there do not enact the reform legislatively.
The Cannabist Company Holdings will report its financial results for the third quarter ended September 30, 2023 before U.S. financial markets open on Tuesday, November 14, 2023.
The Cannabist Company to report third quarter 2023 results on November 14, 2023 before U.S. financial markets open.
Trulieve Cannabis announced the relocation of a medical cannabis dispensary in Melbourne, Florida.
Trulieve Cannabis has added $500,000 to a ballot initiative aimed at legalizing the recreational use of marijuana, bringing its total contributions to $39.55 million, according to a newly filed finance report.
Verano Holdings announced the opening of Zen Leaf Newington, the company’s second social equity joint venture location in Connecticut and fourth cannabis dispensary statewide, on October 13, following a ceremonial ribbon cutting at 9 a.m. local time.
Vext Science has completed the previously announced non-brokered private placement of $11.5 million through the issuance of 67,647,058 common shares at a price of $0.17 per Common Share, including the full exercise of a $1.5 million over-allotment option.
Tier-1 cannabis multistate operator TerrAscend Corp. has made a notable splash in advance of Investor Day presentations at the Toronto Stock Exchange. The company has elevated forward-looking forecasts for net revenue and Adjusted EBITDA from ongoing operations for the entirety of 2023, signaling that business operations are exceeding previously-stated expectations.
For its full fiscal 2023, TerrAscend now expects net revenue and Adjusted EBITDA to register a minimum of $317 million and $63 million, respectively, versus previous a previous forecast of $305 million and $58 million. This represents year-over-year growth of 28% in net revenue and 62% in Adjusted EBITDA from continuing operations—both well above Tier-1 industry averages.
Furthermore, TerrAscend anticipates that its gross margin will surpass the 50% mark, and generate positive free cash flow from ongoing operations during the latter half of the year.
The House GOP’s pick for speaker, Steve Scalise, announced Thursday he will no longer seek the gavel as he confronted a likely insurmountable vote shortage. While Scalise had won a majority of votes in an internal GOP ballot a day earlier, he faced an ever-growing list of Republicans who vowed to support only his opponent, Rep. Jim Jordan, on the floor. The Ohio Republican is now expected to make another run for the position.
Scalise announced his decision on Thursday evening, following a conference meeting in which it became clear that he had no path to winning the 217 votes needed to ascend to the speakership.
House Republicans voted Friday to nominate conservative firebrand Jim Jordan for speaker of the House — the latest twist in a chaotic battle for speakership. Jordan, the chairman of the Judiciary Committee, received 124 votes — still more than 90 votes shy of the 217 he will need to grab the gavel in a vote on the House floor, according to members and aides who were the room. That floor vote has not yet been scheduled.
Jordan had an opponent in the conference vote for speaker: Rep. Austin Scott, who filed to run for the top spot shortly before the vote went down. Scott received 81 votes in the candidate forum.
Jordan had earlier backed out of the speaker race, saying he would cast a vote for Rep. Steve Scalise after the majority leader earned the nomination is a similar closed-door session Wednesday. Scalise backed out Thursday night after he failed to secure the votes needed to become speaker.
The post TDR’s Top 7 Cannabis Developments For The Week Of October 9 appeared first on The Dales Report.tsx senate governor mortality covid-19 canada germany eu ontario
TDR’s Top 7 Cannabis Developments For The Week Of October 9
Poseida promotes cell therapy president to CEO; After IPO, Neumora appoints R&D chief
Young people are cutting back on these habits, says survey
Macro: Sep CPI stuck at 3.7% YOY
Comfort in the Stock Charts (Video Interview)
Ikea Plans Worldwide Price Cuts After Warning: “Time To Buckle Up”
Arnold Schwarzenegger Says Democrats Want To “Ruin” US Cities
Elon Musk’s Tesla just got into a weird new business: selling beer
Hydroxychloroquine Reduces COVID-19 Mortality, Study Finds
Novel catalyst for green production of fine chemicals and pharmaceuticals
International24 hours ago
Stock Market Weekly Update: 3 Valuable Points You Need To Know About the Selloff
Uncategorized21 hours ago
Animal Contraceptive And Antibiotics Detected In Top 10 Popular Fast Foods: Report
Government18 hours ago
China’s Birth Rate Plummets 10% To Lowest On Record
Government22 hours ago
Is Newsom’s Senate Appointment An ‘Insulting’ Pledge Fulfilled?
Government21 hours ago
GOP Lawmaker Flies To Israel To Rescue Americans After ‘Ton of Requests’
Government23 hours ago
WH Ups Pressure On Tuberville To Abandon Pentagon Blockade
Uncategorized12 hours ago
Ferrari to accept crypto payments in the US
International21 hours ago
Ancient Solar Storm Discovered In Tree Rings Reveals ‘Catastrophic’ Event 14,000 Years Ago